Alnylam Moves Forward on Multi-Product RNAi Facility

Aug 04, 2016
By BioPharm International Editors

Alnylam Pharmaceuticals, an RNAi therapeutics company, broke ground on a biopharmaceutical manufacturing facility in Norton, Massachusetts to supply RNA interference-based therapeutics for its clinical and commercial needs, the company announced on April 28, 2016. In an Aug. 4, 2016 press release, Jacobs Engineering Group announced that it was awarded a contract to provide engineering services and procurement for the facility. Construction on the 200,000-ft2 facility is expected to be completed in 2018, and it will initially employ approximately 150 new full-time employees.

“This flagship multi-product facility represents a key next step in Alnylam’s transition toward a commercial stage company. Increased manufacturing capability is vital to support our rapidly growing pipeline of 10 clinical stage programs, two of which are in Phase 3 trials,” said John Maraganore, CEO of Alnylam, in the release.

Sources: Jacobs, Alnylam

native1_300x100
lorem ipsum